Exact Sciences presents Oncodetect MRD and Cancerguard MCED data at AACR 2026. Analysis of what the new TNBC and multi-biomarker classifier findings mean for clinical adoption.
Belay Diagnostics validates its Summit 2.0 CSF genomic assay, strengthening the clinical case for liquid biopsy in CNS cancers. Read the full analysis.
Guardant Health brings its Guardant360 CDx test to Policlinico Gemelli in Italy. Find out how in-house liquid biopsy could reshape cancer diagnostics in Europe.